---
source_pdf: "https://drive.google.com/file/d/1AfnSZqKidJ3xasAgS5kDQ4PoXxTDN9BpqOw2mNH4Zoc/view"
drive_folder: "Research"
type: research

ingested: 2025-12-28
original_filename: "SMB"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/1AfnSZqKidJ3xasAgS5kDQ4PoXxTDN9BpqOw2mNH4Zoc/view)

## Slide 1: SMB slides
SMB slides

## Slide 2: SMB Positioning Diagram

**Applications**
*   **Preclinical / Discovery**
    *   Target ID: Benevolent
    *   Biomarker Discovery: OWKIN
*   **Clinical Research**
    *   Protocol Design: faro
    *   Digital Twins: UNLEARN
    *   RWD / RWE: ATROPOS HEALTH
*   **Commercial**
    *   BD&L: Prudentia Sciences
    *   CDS: iz.ai
    *   CDx: TEMPUS

**SMB Positioning**
*   White-label to partner with application companies for distribution

**Data Sources**
*   'Omics
*   Radiology
*   Patient Records (Medical records (identified and de-identified))
*   Pathology (Whole-slides images, histology)

**SMB Positioning**
*   Provide value to data owners for right to access data and keep model weights

**Models**
*   STANDARD MODEL BIO
*   Large Model Companies:
    *   ChatGPT
    *   AI
    *   Meta
*   Bio Models (Uni-modal):
    *   Evo 2
    *   Virchow

**SMB Positioning**
*   Bring multi-modal, biopharma specific expertise to drive improvements

## Slide 3: Detailed SMB Positioning Diagram with Data Flow

**Applications**
*   **Preclinical / Discovery**
    *   Target ID: Benevolent
    *   Biomarker Discovery: OWKIN
*   **Clinical Research**
    *   Protocol Design: faro
    *   Digital Twins: UNLEARN
    *   RWD / RWE: ATROPOS HEALTH
*   **Commercial**
    *   BD&L: Prudentia Sciences
    *   CDS: iz.ai
    *   CDx: TEMPUS

**SMB Positioning**
*   White-label to partner with application companies for distribution

**STANDARD MODEL BIO** (central entity)

**Models**
*   Large Model Companies:
    *   ChatGPT
    *   AI
    *   Meta
*   Bio Models (Uni-modal):
    *   Biomni
    *   Evo 2
    *   Virchow
    *   MedImage Insight
    *   Ethos

**SMB Positioning**
*   Can leverage other uni-modal models if need be

**Data Sources**
*   Text from Web (Biomedical literature, Clinical trials)
*   'Omics (Protein, RNA, DNA)
*   Path (WSI, H&E)
*   Rad (CT, MRI, X-ray)
*   Clinical (EMRs, ECG)

**SMB Positioning**
*   Provide value to data owners for right to access data and keep model weights

## Slide 4: Clinical Representation and Impact

**SMB represented in orange**

**From any input**
(Diagram of human body with inputs and outputs)

*   **Inputs:**
    *   PATIENT RECORDS
    *   PATHOLOGY
    *   RADIOLOGY
    *   GENOMICS

**To any output**
*   COMPLEX PHENOTYPES
*   SaMD
*   TARGET ID
*   DECISION SUPPORT
*   HYBRID DIGITAL/MOLECULAR TX
*   NOVEL VARIATIONS
*   NOVEL ENDPOINTS
*   PATIENT SCREENING
*   DIGITAL TWINS

Clinical representation of what it means to be a patient. This impacts the entire value chain

**Tahoe represented in purple**
*   **Perturbed cell**
*   **Perturbations**
    *   GENOTYPE
    *   DRUGS
    *   GENE EDITING
*   **Healthy cell**

Understanding at cellular level, narrow to drug discovery

| Stage              | Preclinical / Discovery       | Clinical Research                                | Commercial                                    |
| :----------------- | :---------------------------- | :----------------------------------------------- | :-------------------------------------------- |
| **% impact**       | Indication prioritization     | Trial design, novel endpoints, prognostics,      | Decision support, patient screening, CDx      |
|                    | Target ID / MoA               | digital twins                                    | Development                                   |

## Slide 5: Business Model Evolution

**Business Model Evolution**

Saas
*   Benchling
*   Veeva

Services + Data
*   DATAVANT
*   komodo

Model-as-a-service
*   STANDARD MODEL BIO

Drug Discovery Platform
*   Isomorphic Laboratories
*   TAHOE

Asset-centric
*   nimbus THERAPEUTICS
*   ROIVANT SCIENCES

Why is this different?
*   Xx
*   Yy
*   Zz